{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:29Z","timestamp":1787070929189,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is one of the sub-types of peripheral T-cell lymphomas (PTCLs) that are remarkably refractory and has the potential to have a poor prognosis. The treatment process includes a wide range of treatment modalities, from anthracycline-based regimens that have been used for years to novel agents, such as histone deacetylase inhibitor romidepsin and belinostat. Increased treatment response rates and prolonged survival have been reported in studies with belinostat. Similarly, in this case report, we wanted to share a patient of an advanced age and with a high IPI score, whom we had treated in many treatment lines and maintained a long-term treatment response by administering belinostat.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1213_22","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:54:16Z","timestamp":1719510856000},"page":"1049-1052","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated"],"prefix":"10.4103","volume":"20","author":[{"given":"Figen","family":"Atalay","sequence":"first","affiliation":[{"name":"Department of Hematology, Baskent University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpay","family":"Ye\u015filaltay","sequence":"additional","affiliation":[{"name":"Department of Hematology, Baskent University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma):Results from the Non-Hodgkin's Lymphoma classification project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma:The many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-Cell lymphoma","volume":"156","author":"Xie","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"Aphase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur J Haematol"},{"key":"R6-20241021","first-page":"454","article-title":"Outcome of belinostat in patients with peripheral T cell lymphoma, multicenter real-life data, Turkey","volume":"44","author":"Akdeniz","year":"2022","journal-title":"Osmangazi Journal of Medicine"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for \u0131nitial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classification","volume":"32","author":"Cheson","journal-title":"J Clin Oncol"},{"key":"R8-20241021"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma:Results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1182\/blood.V120.21.4857.4857","article-title":"CHOEP-21 chemotherapy without autologous stem cell transplantation (ASCT) for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in the Northern Part of Thailand","volume":"120","author":"Rattarittamrong","year":"2012","journal-title":"Blood"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/leu.2014.241","article-title":"Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model","volume":"29","author":"Yu","year":"2015","journal-title":"Leukemia"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma:Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1756-8722-6-69","article-title":"Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral tcelllymphoma","volume":"6","author":"Reimer","year":"2013","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1213_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:05Z","timestamp":1787067545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1213_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1213_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2022-06-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}